DALLAS, July 9, 2012 /PRNewswire/ -- Securities
lawyers at Goldfarb LLP are investigating alleged violations of
shareholder protection laws by officers and directors of Amylin
Pharmaceuticals, Inc. (NASDAQ: AMLN) in connection with a buyout
for $31.00 per share to Bristol-Myers
Squibb. Concerned AMLN investors are encouraged to contact attorney
Hamilton Lindley at 877-583-2855 or hlindley@goldfarbllp.com about
their rights and remedies.
"Amylin's recently approved diabetes drug, Bydureon, has been
noted to have huge potential in the diabetes drug market, as a
wholly owned subsidiary of Bristol-Myers," said Hamilton Lindley.
"Seeing this potential, AstraZeneca plans to collaborate with
Bristol-Myers, following the completion of the acquisition, and
making payments to Amylin as a wholly owned subsidiary of
Bristol-Myers. Our potential lawsuit will seek to ensure that all
important information is disclosed so that shareholder interests
are protected in terms of price and information."
Goldfarb LLP lawyers have significant experience representing
shareholders and whistleblowers in securities lawsuits nationwide.
AMLN stockholders – or anyone with knowledge about this acquisition
– should contact lawyer Hamilton Lindley at
hlindley@goldfarbllp.com or 877-583-2855 with questions or
concerns.
Hamilton Lindley
Goldfarb LLP
2501 N. Harwood, Ste. 1801
Dallas, TX 75201
(877) 583-2855 Toll Free Telephone
(214) 583-2233 Local Phone Number
(214) 583-2234 Fax Number
www.goldfarbllp.com
SOURCE Goldfarb LLP